Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.4, 2009-04, pp. : 541-548

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Copper Lowering Therapy With Tetrathiomolybdate as an Antiangiogenic Strategy in Cancer

Current Cancer Drug Targets, Vol. 5, Iss. 3, 2005-05 ,pp. : 195-202

Bentham Science Publishers

Access to resources Recommend Favorite

The use of copper-lowering therapy with tetrathiomolybdate in medicine

By Brewer George J

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 1, 2009-01 ,pp. : 89-97

Informa Healthcare

Access to resources Recommend Favorite

Antiangiogenic therapy through copper chelation

By Sproull Mary Brechbiel Martin Camphausen Kevin

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 3, 2003-06 ,pp. : 405-409

Informa Healthcare

Access to resources Recommend Favorite

The Role of Iron Chelation in Cancer Therapy

Current Medicinal Chemistry, Vol. 10, Iss. 12, 2003-06 ,pp. : 1021-1034

Bentham Science Publishers

Access to resources Recommend Favorite

Essentiality, Toxicology and Chelation Therapy of Zinc and Copper

Current Medicinal Chemistry, Vol. 12, Iss. 23, 2005-11 ,pp. : 2753-2763

Bentham Science Publishers

Access to resources Recommend Favorite